Adventrx Pharmaceuticals (ANX): Where Is ‘Fair Value’?

With 6 weeks to a U.S. Food & Drug Administration (FDA) decision on Adventrx Pharmaceuticals’ (ANX) Exelbine™, an enhanced formulation of the chemotherapy drug, vinorelbine, trading continues to be volatile. The reason?

Diverging opinion with a side of emotions at play.

Vista Capital Partners set a $7.50 price target on Adventrx shares in the latter part of June, two days after Rodman & Renshaw revised their target on the company upwards 355% to $16. Shares quickly leaped to a new 52-week high, on equally impressive volume. 

However, some investors are not as enthusiastic. Growing share volume has accompanied a growing short interest in Adventrx Pharmaceuticals’ shares. Investors betting on a decline in the company’s stock comprised 7.7% of the float at the end of June (NASDAQ.com). To top it off, TheStreet.com analyst Adam Feuerstein added:

Adventrx is overvalued (perhaps wildly so) on a fundamental basis. […]At the moment fundamentals don’t matter, but at some point, they will.

Feuerstein went on to explain that the addressable market for Adventrx Pharmaceuticals’ Exelbine™ is dismal, with U.S.sales of vinorelbine at $7 Million. Yet, this statement differs materially from a similar analysis in 2010, where Feuerstein wrote that the U.S. market for vinorelbine is worth $20 Million annually. In the unlikely event that the market for vinorelbine contracted 65% year-over-year (as the analyst’s research suggests), we took to Adventrx’s SEC filings for a precise answer:

Based on data from IMS Health, total vinorelbine sold in theU.S.in 2009 was approximately 9.4 million milligrams. We estimate that the current average sales price for generic, or multi-source, vinorelbine in theU.S.is between $1.40 and $1.50 per milligram

This puts U.S.sales of vinorelbine between $13.16 Million and $14.10 Million per annum – twice the number which Feuerstein quoted.

Pricing Strategy

Exelbine™, which would aim to replace branded and generic formulations of vinorelbine through its administering benefits, would offer Adventrx Pharmaceuticals pricing power over competitors if granted a unique Healthcare Common Procedure Coding System (HCPCS) product code. According to the company, a unique code would allow Exelbine™ to be quoted at its own price – regardless of the price of substitute products. Let’s put this into perspective with an example.

Microsoft controls the market for Office software. They are the sole supplier of Microsoft Office. While substitute products exist, they are not ‘identical’ to Microsoft’s Office Suite. This gives Microsoft leverage to price their product at a premium to substitutes. Adventrx’s plans for Exelbine fall along the same lines.

According to their annual report, Exelbine will be priced at $5-10 per milligram:

While we have not determined a price for Exelbine if it were approved by the FDA, we expect decision makers to value its unique formulation as compared to Navelbine and its generic equivalents, and we anticipate pricing Exelbine in theU.S.between $5 and $10 per milligram.

Valuation

Adam Feuerstein at TheStreet.com prepared a valuation for shares of Adventrx Pharmaceuticals assuming 50% market penetration for Exelbine by 2013 (that is, in two years). To be more conservative, suppose 33% penetration, and pricing at the low-end.

9,400,000 milligrams * 33% * $5/milligram = $15.67 Million in sales for fiscal 2013.

And, if Feuerstein wanted to know what those sales were worth to shareholders today, we would discount 15% and divide by a fully-diluted 35.67M shares (10Q), resulting in revenue per share of $0.38.  

At this stage, in place of a randomly assigned sales multiple (albeit, it is tempting), we’ll use the industry average price-to-sales ratio of 11.38 to measure ‘fair value’.

11.38 * $0.38/share = $4.32/share valuation.

Conclusion

Adventrx Pharmaceuticals will continue to trade in a volatile range at least until the FDA has rendered an opinion on Exelbine. Using a simple calculation, we showed that shares of this late-stage biotechnology firm are undervalued on the basis of a potential product approval and commercialization efforts. However, Exelbine’s FDA trial could also be the stepping stone for a multitude of products, including Adventrx’sANX-514, a novel, detergent-free reformulation of the chemotherapy drug docetaxel, andANX-188, a compound for the treatment of patients with sickle cell disease.

To support their efforts, cash and equivalents tallied $46.55 Million or $1.30/share, as of the most recent quarter.

Uplisting May Be Next For ImmunoCellular Therapeutics (OTCBB: IMUC)

 

It stands that as of Wednesday, shares of ImmunoCellular Therapeutics (IMUC.OB) have closed above the $2 threshold for 16 consecutive sessions – the most since marking a new 52-week high in March. ImmunoCellular Therapeutics CEO, Dr. Manish Singh, told us earlier this year that his firm would pursue listing their common stock on a national exchange to gain visibility, liquidity and suitability for a broader group of investors (more on this in a moment). Prior to our interview with Dr. Singh, we explained how a successful private placement already qualified ImmunoCellular Therapeutics for listing on the NYSE Amex under ‘standard 3′ (observe below).

 

In mid-May, ImmunoCellular Therapeutics filed its quarterly report, confirming our theory that the firm met listing requirements set by the NYSE Amex. Shareholders’ equity registered above the required $4 million; market capitalization rung north of the minimally permissible $50 million. Unfortunately, at the time, the stock price did not conform.

Rich Adamonis, a spokesperson for the NYSE, told us over the phone that the approval process for listing on the NYSE Amex typically takes from 3-6 weeks. Assuming ImmunoCellular Therapeutics submitted an application to the Amex sometime last month (when the share price broke above $2), the company could get the ‘go ahead’ as early as August, as all listing requirements are now met.

However, the listing itself isn’t a big deal – it’s everything that could come with it that is.

Funds, for instance, are often restricted from buying into companies that trade over-the-counter. Upon listing on the Amex, this restriction would be relieved, allowing greater investment to potentially flow towards ImmunoCellular Therapeutics. Additionally, the up-listing could bear inclusion into a number of small cap indices like the Wilshire U.S. Micro Cap Index, which is tracked by the Wilshire Micro Cap ETF (WMCR), Bridgeway Ultra-Small Company Market Fund (BRSIX), iShares Russell Microcap ETF (IWC), First Trust Dow Jones Select MicroCap ETF (FDM), and a host of others, including industry-specific indices like the Amex Biotechnology Index (ABT).

Inclusion in any index almost instantaneously registers new institutional holders in a company, as funds that mirror an index allocate shares of the newly included company to rebalance their portfolios. This takes from the float, which puts upwards pressure on the share price.

ImmunoCellular Therapeutics is roughly 32% owned by insiders; 11% belongs to funds. Dafna Capital Management LLC is one of two funds that recently started a position in ImmunoCellular Therapeutics. The fund’s chief investment officer was interviewed by Reuters and had the following to say on the topic of biotech companies that are focused on cancer being hot acquisition targets:

We have seen some very successful oncology drugs,” said Fariba Ghodsian, chief investment officer at hedge fund DAFNA Capital. “Novel drugs with novel targets are in demand.

According to NASDAQ.COM, Dafna Capital’s largest allocation is in Pharmacyclics Inc. (PCYC), a clinical-stage oncology firm focused on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Threshold Pharmaceuticals (THLD) and YM Biosciences (YMI) are the only other oncology holdings among the fund’s top 10. ImmunoCellular Therapeutics provides Dafna Capital exposure to an exciting and novel technology in immunotherapy, perhaps modeling Dendreon (DNDN) at a less ‘expensive share price’, to quote the Reuters columnist. One share of ImmunoCellular Therapeutics’ currently trades for about 1/1000th of one share of Dendreon. 

ImmunoCellular Therapeutics expects interim results from their Phase II study of ICT-107 in patients with glioblastoma multiforme (GBM) in the second half of 2012. Phase I studies returned fantastic results with 80% overall survival at the two-year mark compared with historical standard-of-care survival of just 26.5%; median progression free (PFS) survival of 16.9 months compared to the historic median PFS of 6.9 months. According to the same source, the company will also be filing an Investigational New Drug (IND) application with the FDA to move ICT-140, a vaccine for the treatment of ovarian cancer, into clinical studies early next year.

Bullish on Northwest Biotherapeutics (NWBO)? You Should Be.

Late last evening Northwest Biotherapeutics (NWBO) released news stating the company is expanding the number of clinical trial sites for their “ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer“.

This puts NWBO’s brain cancer drug on the fast-track to significant interim data and, eventually, commercialization (upon FDA approval).

This latest announcement follows very significant news from one week ago, which has since spurred the price onwards and upwards, quite notably.

NWBO is now working with Fraunhofer, the largest applied research foundation in Europe, to administer trials in Europe, as well as provide DCVax-Brain for compassionate care uses. What this means is sales in Q2 and yet another source of capital to finance operations.

See our coverage on the significance of those earlier news, including the partnership and approval for compassionate care uses in Europe, here.

Fast-forward to today. NWBO is in late-stage trials for a potential breakthrough product that will treat brain cancer. Dcvax-Brain has two significant advantages over current treatments: effectiveness (think what someone would give to live another year) and limited side-effects (think what patients treated with chemotherapy go through).

NWBO has just signed an agreement to sell this treatment in Europe under compassionate care uses, meaning revenues will soon start flowing in (beginning in this very quarter).

Yet, NWBO still trades for under $60M. To give you a benchmark for the potential inherit in this firm, consider Biovex, a private biotechnology firm that was in late-stage clinical trials for head & neck cancer when Amgen (AMGN) bought them out for $1 Billion. That buyout happened just earlier this year. And Biovex’s clinical data closely resembled the results that NWBO has been reporting in trials.

What Can You Expect? 

More of the same. Superior data from trials and continued expansion of the clinical study of DCvax-Brain in patients with brain cancer. Look for sales to reflect compassionate care uses of DCvax in Europe, in the second quarter. And don’t be surprised to see NWBO continuing to edge higher, incrementally. 

NWBO has the markings of a $100M company just based on where they are today. That, in itself, could mean a handsome return-on-investment (ROI). At another time we’ll look at how Dendreon’s (DNDN) prostate cancer drug made them a $6 Billion company. Their humble beginning is oddly familiar to NWBO, perhaps the firm next in line to introduce a novel brain cancer drug into the market.

Northwest Biotherapeutics (NWBO) Could See a Return to Higher Prices

Historically, Northwest Biotherapeutics (NWBO) has trended at or near its 50-day moving average (observe chart below).

Northwest Biotherapeutics chart

Deviation below the 50-day moving average (MA) has commonly resulted in a buying opportunity, as the price tends to adjust back upwards to the 50MA. Now, for the third time since 2007, Northwest Biotherapeutics shares have deviated significantly (~44%) below their historical price average.

Is there reason to believe the price may presently adjust back to the 50MA?

The scent of material news is looming. Recent SEC filings reveal the company has entered into arrangements with private investors to raise capital needed for funding clinical trials of the company’s immunotherapy drug, DCVax, in brain and prostate cancers. As capital shortfalls have plauged clinical development, a financing agreement would be significant enough to bolster shares back to the 50MA, and beyond.

Speculation aside, Northwest Biotherapeutics (NWBO) has returned meaningful data from clinical trials in Glioblastoma (brain) and prostate cancer, respectfully.

Under DCVax®-Brain, median survival of newly-diagnosed patients with glioblastoma, a common form of brain cancer, was 36.4 months, comparing favorably to the standard of care median of just 14.6 months. Treatment of brain cancer under the standard of care would include surgery, radiation therapy and Temodar, a compound distributed by Merck (MRK). Under this care, however, only 26% of patients live beyond two years; more than 69% have survived after being treated with DCVax.

Invariably, Northwest Biotherapeutics’ strides are aimed at a fairly unsatisfied market, where DCVax®-Brain has shown clinical significance (see figures, below).

Northwest Biotherapeutics DCVax

Northwest Biotherapeutics DCVax 

The end-goal then, perhaps, is a new and superior standard-of-care that includes Northwest Biotherapeutics’ DCVax®-Brain.

DCVax®-Prostate, FDA-cleared to undertake Phase III trials for prostate cancer, competes in a market familiar to Dendreon (DNDN) shareholders. The once small, now $5 Billion biotechnology company found fame in FDA-approved Provenge, which is used to treat prostate cancer. Like Provenge, DCVax®-Prostate is an immunotherapy that ”utilizes a patients own dendritic cells, and an antigen or target protein, to induce an immune response“. Without diving into too great detail on the similarities or dissimilarities, the schedule presented (below) speaks volumes about the data collected in earlier trials of DCVax®-Prostate.

Northwest Biotherapeutics survival data

Evidently, Northwest Biotherapeutics has a legitimate product candidate for the treatment of both prostate and brain cancer. Should the company strike a deal that will fund late-stage trials, investors may very well begin to wager on the success of this organization. Earlier this year, Amgen (AMGN) acquired privately-held Biovex, a biotechnology firm that was developing a vaccine for head & neck cancer. They were in stage III trials when the pharmaceutical giant took notice and offered $1 Billion to buy them out. Northwest Biotherapeutics’ DCvax has shown efficacy that even Biovex’s vaccine fell short of.

Coffee Holding Co. (NASDAQ: JVA) – Shrewdly Overvalued

This past Thursday, Coffee Holding Co., Inc. (NASDAQ: JVA) published results for its first operating quarter of 2011. For the period ended January 31st, net sales were up 20% compared to the same period in 2010. However, in the two trading sessions that ensued the financial report, shares rose 74% to the tune of shrewdly overvalued.

In the press release accompanying financial results for the most recent quarter, the company wrote:

“The increase in net income primarily reflects increased gross profit”.

True. If overhead costs remained stable, and sales grew, then the contributing factor would have to be gross profit. This piqued one inquirer’s interest in that it implied gross margins remained stable. But the company itself concluded in the very same press release that “commodity pressure” and “dramatically increased coffee prices” placed a burden on their business. This would imply shrinking margins.

“Our horizontal integrated business structure combined with our hedging policies helped us to significantly alleviate these higher costs as evidenced by our cost of sales only slightly increasing by 0.02 % during a time when the underlying commodity increased by over one dollar per pound as the fundamentals in the coffee market led to higher futures prices.”

This hedging policy, disclosed in their 10Q filing with the SEC, shows that speculation in the futures market led to a favorable gross margin. The slight 0.02% increase in the cost of sales was, therefore, attributable to a one-time gain on futures contracts. Here’s a detailed look at the disclosure.

 

For the three months ended January 31st, 2011 gains totaled $680,000 versus $135,000 in the comparable period of 2010 (see above schedule). That $545,000 contribution made up the difference in bottom line earnings from one period to the next.

Herein lie two key points.

The first is that an improved bottom line in the most recent quarter is not the result of growing or otherwise enhanced operations.

“The increase in net sales reflects higher sales prices compared to the first quarter of fiscal 2010[...]“

As input prices increased, the company was forced to increase the price at which it distributes its products. While the nominal numbers impressed investors, the 20% jump in net sales does not necessarily mean that quantity sold increased substantially. In fact, by the numbers, it’s difficult to point out any material change from last year.

Further, excluding the one-time gain from futures speculation, gross margins were depressed when compared with the same period in 2010. And income, adjusted for this event would contribute approximately the same earnings per share as in 2010. Therefore the ecstatic reaction in the stock’s market was unjustified.

The second point is that market prices fluctuate – everything from commodities to equities to currency. So to expect gains from futures contracts to rescue the company’s shrinking margins quarter after quarter is a dangerous assumption. Markets are uncontrollable, which exposes the company to potential losses on their derivative bets. In all likelihood, Coffee Holding Co.’s overvaluation was the result of investors assuming uncertain (but favorable) events without factoring in potential risks in this business.

If not the numbers, then what led to the surge in stock price and trading volume? Deja-vu – market speculators. So ask yourself, suppose other investors realize Coffee Holding Co. isn’t the growth story they sought out for. And suppose, next quarter, earnings came in flat, instead of improving over last year’s. Would that justify the stock price sliding back down to $4/share?

Beyond a reasonable doubt Coffee Holdings Co., Inc. is overvalued at its current market price.

Disclosure: I have no position in JVA at time of writing but may initiate a short position in the next 48 hours.

ImmunoCellular Therapeutics (IMUC), Technically Speaking

This Afternoon, ImmunoCellular Therapeutics’ (IMUC) CEO, Manish Singh, Ph.D., is scheduled to present at the 13th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference should attract institutional investment, as fund managers learn of the cancer therapeutics ImmunoCellular (IMUC) is developing. As noted in a written analysis, ImmunoCellular’s lead product candidate, ICT-107, returned stellar results from Phase 1 clinical trials in the treatment of brain tumors.

Above-average share volume has been seen for at least 8-consecutive trading sessions, coincidentally since we began coverage of ImmunoCellular Therapeutics (IMUC). During this period, the stock price has gained $0.50 or 28%, encroaching on a new 52-week high. While drivers such as clinical trial results, product and corporate developments remain fundamental, relative price movement will be the catalyst to market momentum for this small biotechnology firm.

As we explain in the following video, relative price movement is an analysis of the price at a specific point in time, better known as technical analysis. Using IMUC’s chart, we interpret the relative price at this point in time, the key technical drivers moving forward, and what the technical indicators are telling us. 

Regarding the company’s presentation at the 13th Annual BIO CEO & Investor Conference, a webcast of the event will be available at http://www.veracast.com/webcasts/bio/ceoinvestor2011/68111156.cfm


Please note that we have previously been compensated for voicing an independent investment opinion of ImmunoCellular Therapeutics, Ltd. The views expressed are purely our own and do not constitute a buy or sell recommendation. See our disclaimer for details.

About the Internationalization of the Chinese Yuan

One of the fundamental characteristics of the global financial architecture is that the world’s second largest economy maintains a rigidly controlled currency. The concept of currency wars, as initially articulated last year, seemed to have been a criticism of the easy monetary policy of the Federal Reserve. But it is being appropriated and used as a criticism of the lack of flexibility of the Chinese yuan.

The reluctance of Chinese officials to allow its currency to be another shock absorber in the circuit of capital means that other liquid flexible or floating currencies have to shoulder a greater burden of the adjustment. Some, like a well respected analyst at a recent industry conference in New York, suggest that as long as Asian currencies remain under-valued, that the European currencies will remain over-valued, and by implication other currencies as well.

Given the tightly controlled yuan market, the extent of its use offshore is a development that is capturing the imagination of many observers and participants. Entities like the World Bank’s International Financial Corp, the Asian Development Bank, McDonald’s (MCD), Caterpillar (CAT) and some of the largest banks in the world have issued yuan denominated bonds in recent months. Billions of dollars in trade is being settled in yuan. The amount of yuan on deposit outside China is growing rapidly. Some observers suggest that this is the beginning of the Chinese yuan becoming a truly global currency and a rival to the privileged place of the U.S. dollar.

Hong Kong

There is both less and more than meets the eye in terms of the internationalization of the yuan. The internationalization of the yuan is less than it may seem because it has been largely confined to Hong Kong, a special administrative region of China. Yet at the same time, it reveals the savvy financial prowess of the Chinese government and is pregnant with vast potential. At the very least, China has found a way to profit from the speculative interest in the yuan; betting as it were, on its appreciation.

China has allowed an interbank market for the yuan to flourish in Hong Kong since last July. If there is a consensus among hedge funds and other speculators, it is that the yuan is going to appreciate in the short and long-term. On the other side are businesses, often Chinese companies owned or backed by the government, who want to borrow yuan to fund onshore operations. Owing to the strong demand for yuan denominated financial products, the cost of (yuan) capital is less than half of what it is onshore.

The yuan raised in Hong Kong is regarded by Chinese officials as a foreign currency (the common mnemonic is CNH to distinguish it from the onshore yuan CNY). The process by which CNH can be brought onshore—transformed into CNY—is not yet transparent. It has not been standardized as are the procedures for dollars, for which there is a clear channel and necessary steps. The yuan raised in Hong Kong is brought into China on a case-by-case basis.

It appears to be guided by Chinese officials to help achieve policy objectives. The location of the borrowing company’s mainland operation seems to be important as the provincial governments are ultimately behind the process. The sector the borrowing company operates in is also important. If it is for a sector that officials worry about overheating or excess investment, it is reportedly more difficult to get authorities to bring the funds onshore.

Domestic Offshore Market

The number of institutions in Hong Kong authorized to do yuan banking business has increased from around 65 at the start of 2010 to more than 100 by the end of the year. Yuan deposits in Hong Kong (CNH) was near 300 billion (~$43 billion) at the end of 2010, more than quadrupling over the course the year. To put that in perspective, the deposits in the mainland (CNY) are on the magnitude of 60 trillion. CNH accounts for roughly 4.5% of Hong Kong’s M2 money supply and about 10% of the foreign currency component of M2.

China has also been encouraging the use of the yuan to settle trades. In October 2010, the most recently available data suggests that trade worth some $10 billion was settled in yuan in October, doubling from the month before. Overall, imports plus exports were near $70 billion, but a more appropriate metric may be imports from the mainland. In that respect, more than half of Hong Kong’s imports from China were settled in yuan. Note, too, that nearly half of Hong Kong’s imports get re-exported.

Arbitrate opportunities have made the gap between the CNH and CNY nearly disappear. The mid-October 2010 CNH was as much as 2.6% richer than CNY. In recent days, the gap was 0.07%. The wide spread drew Chinese companies’ interest.

Consider a chip maker which was to build a new fabrication plant in the province of Fujian. It would need to import capital equipment. The supplier was unwilling to accept yuan as it is not convertible. The company could send yuan to its Hong Kong subsidiary which can swap it for dollars at the better offshore rate.

The Future of Two Currencies- One Country

The Hong Kong dollar has been pegged to the U.S. dollar since 1983. The peg has come under attack in the past, most notably during the 1997-98 Asian financial crises. Officials creatively defended the band and remain committed to it. Some observers suggest that over time, the yuan will supplement and then supplant the Hong Kong dollar.

Hong Kong banks are allowed to issue yuan raised in bond sales. Hong Kong depositors can increase yuan savings by converting up to a fixed amount of Hong Kong dollars a day to yuan. That cap is currently around $2500 a day. Hong Kong registered companies can convert foreign currencies into yuan in lieu of U.S. dollars. Indeed some recent pressure on the Hong Kong dollar, well above the floor permissible by the peg, may have been stemmed from moving into yuan.

Yet we should not believe for a moment that it is a free market. Chinese officials still retain control of the process; regulating the speed and quantity that CNH can become CNY. Hong Kong Monetary Authority maintains strong local control. It requires that banks document trades and discourages speculation.

The HKMA Chief Executive Norman Chan has outlined four conditions that would need to be met to peg the Hong Kong dollar to the Chinese yuan instead of the dollar:

  • China has an open capital account
  • China has a freely convertible currency
  • China has a mature financial system
  • China and Hong Kong economies are closely aligned

In late 2010, Chan said that none of the criteria had been met.

Evolving Market

China wants to control the pace and draw advantage from the seemingly insatiable demand for yuan exposure. Dim Sum bonds exploded on the scene in 2010. Thirty-three deals raised a cumulative sum of about CNY42.5 billion.

The pace picked up a bit in early 2011, but the bigger story may be synthetic yuan bonds. Investors buy the bonds with U.S. dollars and are paid back in yuan. In January, there have been more issues than all last year and they have raised five times more. Nearly four times more money was raised in January in synthetic yuan bonds than in the Dim Sum market. This market is dominated by Chinese property developers.

In mid-January, China announced that mainland fund managers could raise money in Hong Kong for investment in the domestic market, but 80% of the funds raised must be invested in the Chinese bonds market. Around the same time, China indicated it would allow its companies to make foreign acquisitions using yuan. Also starting in January, the Bank of China (BACHY.PK), the country’s fourth largest bank began offering yuan deposits at its U.S. branches.

These are still early days of the internationalization of the yuan and the Sino-ification of Hong Kong. The yuan accounted for 0.3% of the turnover in the foreign exchange market according to the BIS 2010 triennial survey (actually slightly less than in the prior 2007 survey), which is 1/8 the turnover of the Hong Kong dollar. The internationalization of the use of the yuan is largely a function thus far of converting the special administrative region into an “offshore” center.

More steps toward the internationalization of the China’s capital markets are likely. There is talk that in the coming months, China may allow foreign companies to list their shares on the Shanghai stock exchange. There may be efforts to encourage the Panda bond market (foreign companies issuing yuan bonds on the mainland). The development will take place under the guiding hand of China, for whom stability remains a guiding principle. This evolution will build institutional capacity, but a fully open capital account and full convertibility of the yuan still appears to be at least several years away. It is far too premature to speak of a challenge to the greenback by the redback (yuan), though it continues to catch the fancy of many observers.

Article courtesy of Marc Chandler

Wenr Corp (WNRC): New Cable TV Player Scoring BIG While Trading Under The Radar.

Big things are happening for a small company in the Cable TV business. Just months ago, Wenr Corp (WNRC) was a non-operating pink sheets company with 38 million shares outstanding and a tiny public float of only 13.8 million shares. As a non-op, shares sold at a penny. Today, the share structure hasn’t changed, but the share price is in the mid-teens — the few (so far) who are watching closely, think it has much higher to go.

So what happened with this little pinkie that got investors so excited? Quite a bit, as it turns out. Let’s begin with the purchase of two TV station licenses in a bankruptcy court fire sale for a combined $45,000. The company has created a mini media-empire that many of the bigger players could look to for lessons in inspired deal-making.

With his bargain-priced licenses in hand, company Chairman Dan Green hired and called on Manny Martinez, the Charter Communications Vice President and General Manager for California and Nevada, to turn these licenses into revenue.

As Martinez well knows, after a long career in the cable business, building an entirely new TV station is an incredibly expensive proposition. Martinez proposed a better alternative. Through his guidance, WNRC quickly became the Reno affiliate for both the Azteca America and Mexicanal TV Networks. These are two of the largest and fastest growing Spanish language networks in the US, serving Reno’s Latino demographic of 30%.

WNRC receives the benefit of retransmitting a ready-made day program: Azteca and Mexicanal pay WNRC monthly carriage fees merely for retransmitting their network signals. Besides circumventing the financial strain in having to build a new television network, WNRC has also enter the world of high-margin ad-selling.

Elsewhere the company has begun to lay groundwork for a Small Cap Financial Network that they anticipate launching locally, in the Nevada market, with the intention of expanding nationwide with the help of various national cable providers. The possibility of some future press release announcing nationwide rollout of the new financial network is simply mind-blowing.
 
Not a bad few months work for this duo, but even still they were far from done. How about picking up ownership interests in a couple of radio stations? You know, the kind that are networked nationally like the TV networks WNRC works with – simply retransmitting the national feed and getting right to the meat and potatoes of selling advertising and generating revenue? That is just what they did – first with a popular Latino music station and now with the only jazz station in Reno.

There’s more.

The rigid economy has forced larger cable providers to take a hard look at their operations and cut costs anywhere they can. Several of them came to the conclusion that carrying cable subscribers in outlying, sparsely populated regions are, while still highly profitable, an overhead burden they’d rather do without. Who better to sell them to than a company like WNRC? The company has already acquired a few thousand cable subscribers…and is in non-disclose negotiations for the purchase of several thousand others. Industry-wide, these subscribers are typically valued at $4000 per household. The only thing that makes this even more exciting is that the acquisitions are financed through seller-financing. That’s no joke. And as it turns out, if your team includes a cable industry heavyweight like Martinez, the large companies will finance the sale of smaller 5000 to 20,000 systems.

Green has found the shortcut to revenue and cash flow. Period. He has repeatedly “bypassed” the messy, difficult and expensive work of having to build from scratch and positioned WNRC as the revenue “gatekeeper”. Oh yes, it’s quite remarkable. 

But I saved the best part for last. This guy, Dan Green, has really “got it”. Revenue, Cash Flow, Profitability and Share Structure are what it’s all about. No dilution or big cash outlays for him. In fact, he financed the company with personal funds until it became self-sustaining. Martinez, on his part, is a seasoned pro. He’s always on the prowl for shrewd deals where he’s recognized and respected enough to earn top spot in negotiations.

The relatively few investors who have caught on to what WNRC has accomplished so far, and the cable industry veterans who understand the realignment taking place with smaller outlying cable systems have to wonder just how long this can remain an undiscovered gem.

Article courtesy of a WNRC Shareholder

A Technical Approach to the Trading Week Ahead

I often find portfolio managers and investors describing themselves as top-down strategists. They look for trends at the macro level and apply their findings to individual trades. Spare me the humiliation of having skipped past rigorous scans that lie between the trends and the trading positions themselves, for I’m genuinely curious how these individuals prepare for an upcoming week. In lieu of my own curiosity I thought I’d offer an account of how I prepare for the week that lies ahead using technical analysis. Ah, now there’s something new.
 
Looking for trends at the macro level translates into an analysis of a leading index, such as the Dow Jones Industrial (DJI). I find stocks model the Dow fairly consistently whilst allowing me to deduce simple but potentially profitable trends. Here’s a look at the Dow Jones ahead of Monday’s session, through my eyes.
 
 

 
The Dow Weekly chart points to the formation of a bearish chart pattern termed ‘rising wedge’. Simultaneously volume is seen declining in combination with rising price. This is called negative divergence. Both of these technical indicators warn of an impeding correction. It does not imply that we are headed for absolute chaos or destruction, but rather, that the markets will ‘pull-back’. This lends way for some specific trading ideas. You might, for instance, knowing that the Dow trades downwards this week, short financial stocks. On the other hand you might use this knowledge to leverage your position in a bull or bear ETF, such as FAS or FAZ. But many will look to hedge with gold. Below is a look at SPDR Gold Shares (GLD) from a technical perspective.
 
 

 
Conversely to the Dow, gold is currently trading at support and in the midst of a bullish rising wedge chart pattern (assuming support remains intact). Depending on the severity of a pull-back in the equity market, gold may find itself once again testing resistance and potentially breaking out to new all-time highs. So I’m inclined to believe that gold stocks may benefit from this trend.
 
But where does that leave other stocks? As far as I’m concerned as a technical trader, that depends on the severity of movement to either the downside or the upside in the equity market. A look at the economic calendar reveals that a significant portion of data isn’t due until the latter part of this week. That tells me its unlikely that we will see a breakout, breakdown or significant movement until at least mid-week. This plays a crucial role, as I explain to my Premium subscribers, as it determines how you position yourself in trades that you’ve deemed appropriate based on earlier analysis (above).
 
It means there’s room to speculate with some other trades while your core positions mature. Similarly this period allows you to build your positions. At the end of the day you look back at your initial choices and compare to the current situation. Ask yourself what has changed, why, and how you can adjust to better position yourself for optimum reward.
 
In part, that’s what a technical approach to the trading week ahead may look like…at least it does for yours truly.

11 Reasons Why Apple (NASDAQ: AAPL) Could Fall in 2011

AAPL LogoAfter revolutionizing the technology of media and personal electronic devices for the 21st century, staging one of the greatest comebacks of any company in history, and dominating consumer and investor attention for the past five years, Apple (AAPL) may be setting up for a hard fall.

Down and almost out, Apple was nothing to be too excited about 10 years ago. Its Macintosh computers were the bulk of its product line, and PCs were in almost full control of the market. But with the invention of the iPod, which revolutionized the way we listen to and buy music, Apple began its road to recovery – which eventually led it not only to recovery, but to domination as well.
It’s hard to even imagine what things were like before the iPod. Walkmen, CD players and far-inferior MP3 players would be almost embarrassing nowadays in comparison to the iPod, which has become the icon for music devices in the past few years. And the addition of the iPhone to Apple’s product line was met with almost hysterical excitement, as lines outside of Apple stores became a common occurrence. Add to that a consistently-innovated computer and laptop line, thousands of “Apps” for the iPhone that allow people to do anything from looking up restaurants to turning on their cars, and the seemingly never-ending hype as to what Apple will do next, and it is obvious why Apple has been able to build such a powerhouse out of its brand.
But as is the case with every company, story, and fixation, the party eventually ends. Things can’t improve and improve and improve and improve forever. At some point, what was once popular becomes second-class; what was once innovative, becomes old-fashioned; what was once a well-kept secret becomes a monotonous, repetitive idea that offers no benefit.
What I’m saying is that at some point Apple will no longer sit as loftily as it now does. It could fail to innovate, fail to care for its customers, or simply fail to meet expectations. And when that happens, we can expect “Apple lovers” to snap out of their whole-hearted faithful love-affair, wreaking havoc on the stock price if not also sending the company into frenzy. There is no doubt that Apple is one of the greatest companies in the world, with some of the greatest consumer products and revolutionary technologies. But at what point does the fun end?
 
11 Reasons Why Apple Could Fall in 2011

1) Price Run-Up. Less than eight years ago, you could have bought Apple shares for $7. Today they’re sitting at an all-time high above $325 – more than a 4,600% gain!
Take a look at the following chart:

As you can see, there were plenty of opportunities to buy Apple if you missed the first moves: early 2006, early 2008, late 2008-early 2009, and basically at any point before today. The stock did not move straight up without pause; it offered investors numerous chances to jump in.

But after a 4,600% move, now sitting at all-time highs, and especially after such a steep rise since early 2009 – is there really that much room left to go? Aside from the fact that there are probably plenty of other investment opportunities that will outperform Apple, could such a meteoric rise in stock price continue for that much longer?
 
2) Market Cap. With a market cap of over $298 billion, Apple is now the second-largest company in the world. It recently became the world’s largest technology company, moving past Microsoft (MSFT), which was once in a similar position that Apple finds itself now. Besides for the fact that Apple is by no means the market-share leader in computers or phones, there is one much bigger point that just stands out in my mind. The market cap of Apple is equal to the market caps of IBM (IBM), Hewlett Packard (HPQ) and Dell (DELL) combined!
Moreover, it is hard to argue with the claim that it is much harder for a large company to grow as quickly as it did leading up to that point. In other words, as hard as it is to double a company’s market cap from $50 million to $100 million or from $10 billion to $20 billion, it is exponentially harder to take a huge company like Apple and grow its market cap from $300 billion to even $400 billion. Large corporations are sometimes like large, heavy objects much harder to move.

3)
CEO Steve Jobs. Undoubtedly the most prominent figure in Apple, if not the entire technology space, Steve Jobs has been the mastermind and visionary behind much of the company’s success. Yet while Jobs should be granted the utmost credit for his achievements, two issues could still derail the company.
First, his health is of major concern to the future of Apple. In 2004, Jobs announced that he had been diagnosed with pancreatic cancer. His health has been repeatedly scrutinized over the past few years, with Bloomberg even mistakenly publishing a 2,500-word obituary of Jobs in 2008. In April 2009, Jobs underwent a liver transplant, further pointing to the heightened issue of his health.
What happens if Steve Jobs is no longer able to lead Apple? The man who has been behind Apple’s revival and surge to the top of the technology world is seen by many to be vital to Apple’s continued success. Yes, he has established a very strong foundation on which the company can continue to build. But the loss of his vision and continued leadership will hurt the company in the short-term if not put a major damper on its growth in the long-term. Even if strong leadership is available to replace him, you can surely bet that many stockholders would be selling their shares if anything were to happen to him.
The second issue, which has been the downfall of many powerful men and innovative companies, is Jobs’ arrogance. Jobs has downplayed Apple’s surpassing Microsoft in market cap, rejected Adobe’s (ADBE) Flash technology for use in his own company’s products, and bashed competitors like Research in Motion (RIMM) and Google (GOOG). His arrogance has obviously brought him the success he now enjoys, but some of the excessive and unnecessary arrogance he may be guilty of could prevent Apple from taking part in new ventures, new ideas and new partnerships, and could even make Apple a target. One of the most important rules of wisdom and success is being open to new opportunities and not thinking that nobody else can offer good ideas. We’ll see how this one plays out.

4)
Extreme Expectations. After shattering analyst estimates again and again, expectations for Apple are higher than ever. They just haven’t ceased to amaze almost everyone with their record numbers, continuous innovation, and growing grasp of market share. There simply is no company out there like Apple.
But after exceeding investors’ expectations time and time again, is Apple setting up for disappointment? With 47 out of 50 analysts covering Apple maintaining a “Buy” rating and the remaining 3 a “Hold” rating, it’s hard to say investors could be any more bullish than they already are. Almost no one dares to bet against or even speak poorly of Apple; analyst price projections are hovering in the $400+ dollar range; and with Apple touted as everyone’s favorite stock for years now, it could be that all the high growth, big expectations, and future opportunities are already priced in. What happens if Apple slips or even just fails to meet the sky-high expectations that have been set for it? It’s understandable that Apple will drop if it completely screws something up; but what if it just fails to exceed expectations? After exceeding expectations for years, investors’ won’t settle for just meeting expectations. If Apple can’t continue on its course for growth, and do so in tremendous fashion, it could begin to lose its luster. And if it loses its luster, you can bet that many of those invested in Apple will begin to pull their money out in search of better investment opportunities. Nobody remains a crowd favorite forever.

5)
Anyone Left to Buy? After dominating the headlines, media coverage, and the minds of investors for years, is there anyone left who hasn’t bought Apple yet? Almost every fund and institution is invested in Apple; your grandmother is probably invested in Apple. If it’s no longer a well-kept secret, is it really a great investment anymore? And is there anyone left to swear to it? With all the opportunities to invest in it, I find it hard to believe that there are that many people left to buy it. Anyone who has wanted to already has. And though there may be some investors who may get into it again or even for the first time, there is a higher chance that those who own it will sell it at $325 – the new investors would, in effect, be buying from those who have owned it for a while. Smart money will be selling to last-to-get-in investors.

6)
Declining Quality. Apple used to be known for its product quality and customer service, but lately it appears it has been cutting some corners. Understandably so, as Apple tries to grow rapidly and has to keep up with demand and strict time schedules, it sometimes comes across some issues, such as getting its products out on time. But at the same time, a company that grows so quickly sometimes can’t keep up with quality and customer service; it simply doesn’t have the time or resources.
And where did we see this happen? The iPhone was shipped out as soon as possible, and ended up having faulty antennas. To make matters worse, Apple refused to recall the phones and shipped out iPhone “bumpers” instead. Moreover, many iPhones are functioning poorly – just ask some of your friends who own one. iPods have been dying on people for years, for no apparent reason. I’ve even heard people complain about the laptops recently – something Apple has never had problems with. And now, the iPad has been made with a reflective surface, which makes it almost impossible to use in the sunlight – how can anyone take it to the beach or use it outdoors? The Kindle, on the other hand, is made with a non-reflective surface, and avoids these issues. Apple must address these issues and keep up with quality control, or it faces the threat of losing loyal customers.

7) Innovation?
Apple is where it is today because it was able to introduce revolutionary products and continuously innovate them. But after a few generations of iPods, iPhones and laptops, innovation is somewhat lacking. It’s just not that easy to continuously improve on an already-successful product. Take the iPod, for example: it started off as a music-only, black-and-white display device. Then came color, video, internal speakers, touch-screen, Internet, and many other features. But what else is really left? Much of the good features have been introduced already. Many have therefore claimed that the iPods, iPhones and computers are now part of Apple’s core product line – meaning they will continue to grow, but fairly steadily.
The iPad is supposedly Apple’s new focus. I will admit that it’s an interesting and probably useful gadget. But is it really as innovative as investors believe it to be? To an extent, it’s really just a big iPhone or small laptop. And it also cannibalizes some of the iPhone, iPod and laptop sales. Since it offers very similar features to Apple’s other products, there is not much benefit in owning the iPad if one owns the iPhone, iPod and laptop. The iPad may just have been the result of Apple’s dire need to innovate, but innovation may have plateaued.

8 ) Competition.
Apple has hogged the spotlight and much of the smartphone and tablet market. But as other companies see the benefits and opportunities in the space, they will begin to ramp up the competition. The Android and the Blackberry continue to be threats to Apple’s iPhone market share, with Android actually growing faster. The iPad’s relative success also has interested companies like Samsung (SSNLF.PK), HP and Research in Motion to introduce their own respective tablets. It’s only a matter of time before Apple loses its “first-to-enter” role and faces the reality of a market with increasing competition. Another sign of Apple’s struggles is its recent sale of iTunes gift cards for less than their face value. Best Buy (BBY) recently sold $50 iTunes gift cards for $40. A 25% sale seems pretty desperate; it tells me that even Apple doesn’t believe its prices are justified. Apple does have the ability to remain on top and offer the most appealing products, but it definitely won’t be easy as it has been until now. And that could easily send the stock price lower.

9)
Hacking and Viruses. Unlike PCs, Apple computers have been known to be very resistant to viruses. While PCs have been plagued by hackers, viruses and other similar issues, the Apple system has been relatively safe. But as Apple computers continue to sell at an increasing rate, viruses and new problems are more likely. And if Macs begin to wear down at a quicker rate, they could lose some sales. My strategy has been to buy three PCs for the price of one Mac. Apple computers are just too expensive to justify, in my opinion; I’d rather buy three PCs over the course of a few years for the same price I’d be paying for one Apple laptop. That way, if I get a virus on one computer, I can just buy a new one without worrying about all the money I’ve spent. Unless Apple can continue to protect itself from viruses and maybe lower its prices a bit, it may face some fierce challenges.

10)
Weight in S&P 500 and NASDAQ 100. As Apple shares continued to rise, they have carried the broader market and indices with them. Apple is second only to Exxon (XOM) in the S&P 500 in terms of weighting, and makes up over 20 percent of the NASDAQ 100 (QQQQ), equal to the weighting of Microsoft, Google, Oracle (ORCL), Cisco (CSCO), Intel (INTC), Amazon (AMZN), and Research in Motion combined.
That means that for every one percentage point that Apple gains or loses, its impact on the NASDAQ 100 equals much bigger moves in any other individual stocks or even an equal move in the 6 next-biggest companies. In other words, the market and the indices heavily depend on Apple to continue to carry them upward; if Apple begins to fall, it will drag the rest of the market along with it. And regardless of how the other companies are doing, if investors start seeing the market drop, they are prone to avoid the market. Also, Apple’s weighting in the index will be up for review if its weight reaches 24% of the index. If that does happen, Apple’s weighting will be reduced, which will in turn result in less broad-market ETF money being invested in Apple. Right now, money being invested in the NASDAQ 100 through the QQQQ is being allocated heavily to Apple; if Apple’s weighting is reduced from 20%+, however, less money will be allocated to it, which could result in a weakening stock price.
Apple’s heavy weighting in both the S&P 500 and NASDAQ 100 make it the benefactor of a large portion of ETF and broad-sector investments, as allocations are based on a stock’s respective weighting. But at the same time, Apple’s heavy weighting makes it susceptible to a big drop if investors pull out their index ETF or funds, or if Apple’s weighting is recalculated in the NASDAQ 100. The market’s tremendous dependency on Apple is something to take note of.

11)
Poor Use of Cash. With over $25 billion in cash on its balance sheet, Apple is not efficiently putting its money to work. With these massive cash levels, Apple could have paid a dividend to shareholders, buy back stock, or even buy a few companies with promising technology or services. Instead, Apple is not rewarding its investors and isn’t improving through acquisitions. Its idle cash may be due to the uncertainty about the market or simply due to Steve Jobs’ arrogance in thinking the company doesn’t need to acquire any smaller companies. Either way, however, Apple isn’t making the best use of its resources.
Apple has been on top for years now. It is the favorite of many funds, individual investors and the media. It has revolutionized the technology and culture of music, mobile phones and computers. And it is expected to continue to shock the world with its capabilities. But expectations may simply be too high. After a 4,600% parabolic rise in stock price, the involvement of almost every investor, extreme expectations as to Apple’s future, a CEO with health issues and potentially-blinding arrogance, a tremendous market cap which could prevent it from growing as quickly as it has, increasing competition, slowing innovation, and declining quality and customer service, Apple’s euphoric peak may be rapidly approaching. With an almost euphoric position in the business and investment world, it may just take a small slip or a failure to exceed expectations to send Apple stock tumbling, triggering a snowball effect that sends institutions and investors running for the exits.
There has been no proof yet of Apple stock price slipping, but it has been stuck near the $320 range since October. Such a sideways move could be a sign of distribution at the top – as smart investors sell their shares to newcomers. Unless Apple can shoot out of this range, it may be setting up for some trouble. The best move for investors would be to wait and see which way it moves, and maybe even take some profits; with all the issues we’ve discussed, there may be too much risk out there.

 

Article courtesy of Yoni Jacobs of Chart Prophet Capital